SCHEMBL4899880

SCHEMBL4899880

Cc1ccc(-c2cc(-c3ccccc3)c3c(n2)sc2c(N)ncnc23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
PPARG P37231 3/20 0.62
NR2E3 Q9Y5X4 3/20 0.62
NCOR2 Q9Y618 3/20 0.62
MCL1 Q07820 2/20 0.62
POLB P06746 1/20 0.62
LIMK1 P53667 6/20 0.58
HPGD P15428 4/20 0.55
MAPT P10636 3/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 1/20 0.55
CLK1 P49759 2/20 0.52
CDC7 O00311 5/20 0.51
DBF4 Q9UBU7 5/20 0.51
PLK4 O00444 1/20 0.51
IKBKB O14920 1/20 0.51
AURKA O14965 1/20 0.51
CHUK O15111 1/20 0.51
ROCK2 O75116 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899938 0.93 LIMK1 (0.66) KDM4EPPARGNR2E3NCOR2MCL1
SCHEMBL4900157 0.89 HPGD (0.62) KDM4EPPARGNR2E3NCOR2MCL1
SCHEMBL4902783 0.88 PPARG (0.64) KDM4EPPARGNR2E3NCOR2MCL1
SCHEMBL259291 0.86 CDC7 (0.66) KDM4EPPARGNR2E3NCOR2MCL1
SCHEMBL4905558 0.86 CDC7 (0.66) KDM4ELIMK1HPGDMAPTALDH1A1
SCHEMBL4899003 0.82 MEN1 (0.59) KDM4EPOLBLIMK1MAPTKMT2A
SCHEMBL4894356 0.81 HPGD (0.58) KDM4EPOLBLIMK1HPGDMAPT
SCHEMBL4899997 0.79 MAPT (0.50) KDM4EPOLBLIMK1HPGDMAPT
SCHEMBL12969725 0.78 LIMK1 (0.51) LIMK1MAPTCLK1CDC7DBF4
SCHEMBL4903351 0.78 CDC7 (0.64) POLBLIMK1HPGDMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012131297-A1 PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE BAELL JONATHAN BAYLDON (AU) 2012-10-04 WO disclosed
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses CYWIN CHARLES L 2008-01-10 US disclosed
US-7291733-B2 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
EP-1673374-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
US-20050101601-A1 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-05-12 US disclosed
WO-2005035537-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101601-A1 Substituted tricyclic heterocycles and their uses LTC4S, NQO1, CBR3 KDM4E 3715/4885PPARG 550/4885NR2E3 1485/4885
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses LTC4S, NQO1, CBR3 KDM4E 3715/4885PPARG 550/4885NR2E3 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.